Powder: -20°C for 3 years | In solvent: -80°C for 1 year
JMV 2959 is an antagonist of growth hormone secretagogue receptor type 1a (GHS-R1a) (IC50: 32 nM).
Description | JMV 2959 is an antagonist of growth hormone secretagogue receptor type 1a (GHS-R1a) (IC50: 32 nM). |
Targets&IC50 | GHS-R1a:32 nM |
In vitro | JMV 2959 does not cause any intracellular calcium mobilization by itself[1]. |
In vivo | JMV 2959 dose-dependently reduces the startle response (F(3.42)=4.4, p<0.01) and enhances prepulse inhibition (PPI) (F(3.42)=3.9, p<0.05) in the prepulse inhibition paradigm. JMV 2959 (6 mg/kg) causes a obviously suppression of locomotion on days 1 to 7 relative to baseline day 0 (F(7,49)=2.21, p<0.05). When administered alone, it does not increase food intake and does not obviously stimulate growth hormone (GH) release[1]. The alteration in the startle response is mainly due to a 27% decrease in the startle seen in the highest dose of JMV 2959 (6 mg/kg) compare to vehicle (p<0.05)[2]. Results also reveal a significant interaction between JMV 2959 treatment and day (F(1,14)=4.397, p<0.05)[3]. |
Molecular Weight | 508.61 |
Formula | C30H32N6O2 |
CAS No. | 925238-89-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
JMV 2959 925238-89-7 Others JMV-2959 JMV2959 inhibitor inhibit